MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company, announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported total revenue of $7.3 million for Q4 2025, which is a decrease of 16% compared to $8.7 million in Q4 2024. For the full year 2025, total revenue was $33.0 million, down 15% from $38.6 million in 2024. Core business revenue for 2025 was $29.6 million, reflecting a 9% decrease from the previous year. The company also reported a net loss of $44.6 million for 2025, compared to a loss of $41.1 million in 2024. Despite these challenges, MaxCyte is optimistic about its future, providing revenue guidance for 2026 of $30 million to $32 million, which includes core revenue expectations of $25 million to $27 million and approximately $5 million from its Strategic Platform License (SPL) Program. The company ended 2025 with $155.6 million in cash and investments, down from $190.3 million in 2024. MaxCyte's leadership remains focused on expanding its SPL portfolio and driving growth in its ExPERT electroporation platform and SeQure assay services. The company is also preparing to support up to four therapies in Phase III clinical trials by the end of 2026, which underscores its commitment to advancing cell and gene therapy.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.